Seeking Alpha

Repligen (RGEN -0.5%) slips after its Q4 EPS misses estimates. Revenue jumped 160% Y/Y however,...

Repligen (RGEN -0.5%) slips after its Q4 EPS misses estimates. Revenue jumped 160% Y/Y however, led by strength in its bioprocessing business and higher royalty revenue from Bristol-Myers Squibb (BMY) and Pfizer (PFE). looking forward, the company see FY13 net income coming in around $18M - $20M.

Check out Seeking Alpha’s new Earnings Center »

From other sites
Comments (1)
  • Sondra Newman
    , contributor
    Comment (1) | Send Message
     
    CORRECTION? There seems to be a mistake; Repligen beat any Q4 EPS estimates that I am aware of, and not insignificantly so!
    7 Mar 2013, 01:20 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs